Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening
|
|
- Blake McKenzie
- 6 years ago
- Views:
Transcription
1 Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen
2 Disclaimer Race classifications are described as per the South African government classifications and are not meant to be discriminatory nor pejorative.
3 Background on HIV epidemic Antenatal Survey % 35 Blood donors %,35 3,26 29,5, ,8,23,25 2,22,2 15,15 1 5,6 1,74,5 RR 26/Million,1,5, Antenatal survey DoH blood donors SANBS
4 Collections by race and donor type 7 over 1 years White Indian Coloured African New Rejoin Repeat
5 x/1 yields x/1 Concordants 12 1 HIV rate NAT yields serology yields Concordants
6 % Collections % HIV Collections and HIV rate in repeat donors 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% % African Non African African HIV+ Non African HIV +,3,25,2,15,1,5,
7 % Collection % HIV Collections and HIV rate in new donors 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% % African Non African African HIV+ Non African HIV + 3,5 3, 2,5 2, 1,5 1,,5,
8 x/1 x/1 HIV rates by donor type and classification NAT yield rate HIV concordants New Rejoin Repeat New Re-Join Repeat
9 Number (%) of HIV infection category New Rejoin Repeat Inter-don interval days (p)# Total NAT yields* 137 (1.3) 44 (1.9) 31 (12.) 11 (p<.5) 482 (3.1) Serology* Yields 186 (1.7) 17 (.7) 3 (.1) 781 (p<.5) 26 (1.3) Concordant 1545 (97.) 2285 (97.4) 228 (87.9) (95.6) Total 1868 (1) 2346 (1) 2512 (1) (1) *p value <.5 when comparing proportion of repeat and rejoin donors with new donors # p value <.5 when comparing interdonation intervals of NAT and serology yields with concordants (student t test)
10 Donor Type Non African 4,5 4, 3,5 3, 2,5 2, 1,5 1,,5, Repeat Rejoin New Repeat Rejoin New Risk factors NAT yield/1 Ethnicity African White Indian Colour African Repeat Rejoin New
11 x/1 HIV NAT yield/1 by age and gender to 19 2 to to 3 31 to 4 41 to 5 51 to 6 16 to 19 2 to to 3 31 to 4 41 to 5 51 to 6
12 % HIV by ethnicity and donor type Donor type Category Race New Rejoin Repeat p value (new vs repeat) HIV positives White <.5 Indian <.5 Coloured <.5 African <.5 Total <.5 NAT yields White Indian Coloured African Total <.5
13 p24 antigen reactivity (%) of NAT yields Negative Positive Total 26 8 (53) 7 (47) (38) 18 (62) (73) 9 (27) (68) 12 (32) (68) 13 (32) (63) 23 (37) (55) 25 (45) (67) 25 (33) (63) 22 (37) (53) 24 (43) 56 Total 285 (62) 178 (38) 463
14 Early dynamics of HIV markers and estimates of lengths of WPs rd gen Western blot 2 nd gen Weusten J et al. Transfusion 211;51:23-15 Zaaijer et al. Lancet 1992;34:77-2 Fiebig EW et al. AIDS. 23;17: Apertrei AIDS 1996;1:F57-6 Vermeulen et al, Transfusion 213;53: days Source of data Weusten 5.3 Vermeulen Clade B seroconversion panel data 2.8 Fiebig Zaaijer 5. 38% p24ag+ Apetrei 3rd gen rd gen Non clade B (A, E, G) seroconversion data Clade C NAT vs p24 Ag yield ratio data
15 Residual risk methodology Incidence rate-wp risk day equivalent model 1 No Repeat donations No. Seroconverting donors Harmonic mean of interdonation interval MID 5 = 1 95% LOD = 18.4 copies/ml* 5% LOD = 2.7 copies/ml* 2 copies/virion NAT WP 4.3 days NAT Yield WP ratio model 1,2 No of NAT yields No of donations NAT WP = 4.3 days NAT+ Ab- = 15.4 days (clade B) NAT+ Ab- = 16.4 days (clade C) NAT+,p24Ag- = 1.1 days NAT+, p24 Ag+=6.3 days RR = R Days N seroconverting repeat T between N repeat donations RR = WP NAT T1 (WP HIV Ab WP NAT)(T2) NNAT yields N all donations 1. Weusten Transfusion 211;51: Busch Transfusion 25;45:254-64
16 Comparison of models to determine residual risk per million WP Incidence rate-risk day equivalent model WP ratio model Lengths of WP used Repeat Lapsed Repeat + Lapsed Repeat + Lapsed Pre-NAT WP Clade B Pre-NAT WP Clade C Pre-p24 Ag WP Clade C MID 5 =1 virion
17 Residual risk per million Number of HIV seroconversions Trend of residual HIV transmission risk HIV seroconversion Risk days model WP ratio Model (MID 5 =1 virion, Clade C parameters)
18 Residual risk per million Trend residual HIV transmission risk by donor type New Lapsed + Repeat All (WP ratio model, MID 5 =1 virion, Clade C parameters)
19 Residual risk per milion Trend residual HIV transmission risk by race Non African African WP ratio model, MID 5 =1 virion, Clade C parameters)
20 Residual HIV transmission risk by donor type and ethnicity RR x:million (MID 5 =1) African Non African All New Repeat & Lapsed All New 1:12,548 1:323,438 1:26,264 RR 1:x Repeat & Lapsed 1:15,174 1:37,342 1:75,47 All 1:14,349 1:371,776 1:61,557 WP ratio model, MID 5 =1 virion, Clade C parameters)
21 HIV ID-NAT breakthrough infection Donor Recipient Transfused unit Index donation Recipient Date Bled 19/9/214 4/12/214 14/2/215 Unit number Transfused date 28/9/214 Started ARV 28/1/215 Prism HIV S/CO NAT S/CO Viral load 936 copies/ml CD4 578 Lookback investigation HIV-1 Subtype C 1% boot strap in phylogenetic sequencing Observed risk 1:7.7 million
22 HIV NAT breakthrough cases Country Blood Product Storage Screening time Assay days 5% LOD cps/ml 95% LOD cps/ml Pool size Test Failure Break-Through Cases Approx Estimated Cps/mL Viral load plasma copies etimate method ml transfused Recipient Infected Reference Germany RBC In-house 96 64TaqMan 2 128, Yes Schmidt M et al. Transfusion 29;49: Germany RBC In-house TaqMan 2 256, Yes Chudy M et al. Transfusion x Viral Load Below Detectable Level Germany PLT In-house 24 TaqMan 24 No Kalus U et al., Transfusion 29;49: Germany RBC Gfe Blut No Muller B. Transfusion. 213;53: France RBC Nuclisens- Ampliscreen % LOD Yes Najiouallah F et al. J Med Virol 24;73: USA FFP Duplex % LOD Yes Phelps R et al. Transfusion 24;44: USA RBC Duplex % LOD Yes Phelps R et al. Transfusion 24;44: USA FFP Duplex % LOD Yes Stramer S et al. Transfusion 23;43:Supplement :4-41A USA RBC Duplex % LOD No Stramer S et al. Transfusion 23;43:Supplement :4-41A USA RBC In-house 24 18NGI b 2 36 Yes Delwart ELet al. Vox Sang 24;86: Singapore PLT No NAT 5Probit Yes Ling AE et al. JAMA 2; 28:4: Singapore RBC No NAT 5Probit 2 1 Yes Ling AE et al. JAMA 2; 28:4: S. Africa RBC No NAT 31Probit 2 62 No Ferriera MCet al. Transfusion 26;46: S. Africa PLT No NAT 31Probit 2 62 Yes Ferriera MCet al. Transfusion 26;46: Italy RBC No NAT 98TaqMan No Zanetti et al. Transfusion 27;47: Denmark PLT In-house Abbott RT Yes Harritshoj Let al. Transfusion 28;48: Denmark RBC In-house Abbott RT Yes Harritshoj Let al. Transfusion 28;48: Japan RBC AmpliNAT % LOD 2 14 Yes Satake M et al. Journal of Hematology 24;8:36-1 USA RBC Duplex % LOD Yes Laffoon et al, MMWR 21;59: Greece RBC No NAT % LOD Yes Hatzakis et al. (personal communication, 26) Spain RBC 28Ampliscreen Ampl Monitor 2 27 No Alvarez et al. Transfusion 216;56; Spain PLT 2Ampliscreen Ampl Monitor Yes Alvarez et al. Transfusion 216;56; Spain FFP-MB Ampliscreen Amp Mon Yes Alvarez et al. Transfusion 216;56; Japan RBC TaqScreen % LOD 2 82 No Shinohar N. Transfusion 214;54: Japan FFP TaqScreen % LOD Yes Shinohar N. Transfusion 214;54: Brazil RBC 11in house probit 2 87 Yes Salles NA. Transfusion 213;53: Thailand RBC TaqScreen % LOD Rujirojindakul P. Vox Sang 215:19 Suppl P Yes (abstract) SANBS RBC Ultrio Plus % LOD 2 54 Yes Vermeulen M personal communication
23 probability HIV transmissibility in NAT breakthrough cases 1% 9% 8% 7% 6% 5% 4% 3% 2% 1% % FFP PLT RBC transmission MID 5 =96 copies= 48 virions Non transmission copies/ml
24 Impact of MID 5 on overall residual HIV transmission risk MID 5 x/million 1:x :61, :9, :36, :2,4,816 Observed rate.13 1:7,692,37 Possible reasons for lower observed rate: 5% mortality rate 18% adult population already infected Poor ability to contact patients post discharge
25 Conclusions Yield ratio and incidence rate models were comparable when using same WP (risk day) estimates No difference in residual risk between repeat and lapsed blood donors No difference in NAT yield rate and in residual risk in new, repeat or lapsed donors within African donors (and within non African donors) Difference and trends in NAT yield rate and residual risk depends on donor demographics Estimated residual risk is >1 fold than observed rate The implementation of ID-NAT has enabled SANBS to increase the African donor base and maintain the RR 18/million window period donations compared to 26/million in 25 (Pre-NAT)
26
Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationMulticenter efficacy study of HBV, HCV and HIV blood screening scenarios
Multicenter efficacy study of HBV, HCV and HIV blood screening scenarios Steven Kleinman, Nico Lelie, Roberta Bruhn, Brian Custer, Michael Busch and the international ID-NAT user group Blood Systems Research
More informationISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer
ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer Questionnaire on NAT Screening of Blood Donations for an International Forum on 10 years of NAT Screening
More informationCalibration and stability of WHO and secondary viral standards
Calibration and stability of WHO and secondary viral standards Nico Lelie, Harry van Drimmelen and the International NAT Study Group Facilities DDL Diagnostic Laboratories Outline Calibration of WHO and
More informationProbability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014
Probability of false initial and repeat ID-NAT reactive donations Marion Vermeulen IPFA Rome 2014 Overview of SANBS SANBS is a non profit organization Provides a vein to vein blood transfusion service
More informationDISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS
DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS SANBTC Sun City, South Africa 28 th 31 st August 2017 Marion Vermeulen, Karin van den Berg, Genevieve Jacobs, Brian Custer, Ronel
More informationQuantification of HBV, HCV genotype and HIV subtype panels
Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,
More informationIn October 2005, the South African National Blood
DONOR INFECTIOUS DISEASE TESTING Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk_3355
More informationErgebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI
Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)
More informationChallenges in HBV detec1on in blood donors
Challenges in HBV detec1on in blood donors Jean- Pierre Allain Dept Haematology, University of Cambridge, UK Phylogene1c analysis of human and ape HBV over 1me of evolu1on (Pareskevis et al, Hepatology
More informationUpdate from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationTransfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening
Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram Timeline of introduction of microbiological tests
More informationCALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD
CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories
More informationLookback studies to assess viral risks The French experience
Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance
More informationStability of native, lyophilized and inactivated standards
Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization
More informationNAT Screening of Blood Donations in NBC, TRCS
IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine
More informationHEV Assay Development Update
HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening
More informationtransfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of
Haemovigilance and the residual risk of transfusion-transmissible Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations
More informationImpact of multi-dye multiplex technology on testing algorithm
Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT
More informationrisk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)
Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)
More informationRoutine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors
Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationUvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication
UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationAssays to Address Emerging Threats to Blood Safety
Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of
More informationR Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Eurosurveillance, Volume 10, Issue 2, 01 February 2005 Surveillance report HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C AND HEPATITIS B INFECTIONS AMONG BLOOD DONORS IN GERMANY 2000-2002: RISK OF VIRUS TRANSMISSION
More informationSince 1973 all blood donations in the Netherlands
ORIGINAL RESEARCH Rare transmission of hepatitis B virus by Dutch donors with occult infection Ryanne W. Lieshout-Krikke, 1 Marian G.J. van Kraaij, 2 Fikreta Danovic, 2 and Hans L. Zaaijer 1 BACKGROUND:
More informationFDA Reentry Guidance
FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process
More informationP0064 ViraQ HIV-1 Check 125 P0064
P0064 ViraQ HIV-1 Check 125 P0064 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use...
More informationSource Plasma Safety
Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe
More informationDiagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationRecent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence
Recent advances in development and application of assays/algotithms for detection of recent HIV infections and estimation of incidence Michael Busch, MD, PhD Blood Systems Research Institute University
More informationOverview of the testing strategy stages that the Japanese Red Cross has gone through (HBV, HIV)
2014/LSIF/PD/006 Overview of the Testing Strategy Stages That the Japanese Red Cross (JRC) Has Gone Through (HBV, HIV) - The JRC Approach to Donor Recruitment in the Era of Aging Population Submitted by:
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationHBV-DNA reference panels
HBV-DNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HBV-DNA panels
More informationAdverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP)
Adverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP) Constantina Politis Hellenic Coordinating Haemovigilance Centre (SKAE) Background Pathogen inactivation is expected
More informationNucleic Acid Testing to Detect HBV Infection in Blood Donors
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Nucleic Acid Testing to Detect HBV Infection in Blood Donors Susan L. Stramer, Ph.D., Ulrike Wend, Daniel Candotti, Ph.D., Gregory
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More informationCTYOMEGALOVIRUS (CMV) - BACKGROUND
CTYOMEGALOVIRUS (CMV) - BACKGROUND PURPOSE The flowing information provides guidance on the use of CMV negative blood components provided by the blood bank at the Royal Children s Hospital (RCH) including
More informationCBER update and International Collaboration for development of HIV variant panels
CBER update and International Collaboration for development of HIV variant panels Indira K. Hewlett, Ph.D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA XXII SoGAT meeting HIV genetic diversity:
More informationTransfusion-transmitted Cytomegalovirus
Transfusion-transmitted Cytomegalovirus Can you confidently abandon CMV seronegative products in the modern era of pre-storage leukoreduction? Jeannie Callum, BA, MD, FRCPC Really? Are we still talking
More informationAnticipating (re)emerging infections to ensure blood safety
Anticipating (re)emerging infections to ensure blood safety Pierre Tiberghien Etablissement Français du Sang, St-Denis and Université de Franche-Comté, Besançon, France IPFA/PEI 23rd International Workshop
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS
European Medicines Agency Evaluation of Medicines for Human Use London, 20 May 2009 Doc. Ref. EMEA/CPMP/BWP/125/04 Rev.1 Appendices COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT APPENDICES
More informationMSM DONOR POLICY: STUDIES FROM THE USA AND OTHER COUNTRIES. Brian Custer IPFA PEI Workshop Rome 22 May 2014
MSM DONOR POLICY: STUDIES FROM THE USA AND OTHER COUNTRIES Brian Custer IPFA PEI Workshop Rome 22 May 2014 Financial Disclosure Nothing to disclose International Context for Blood Donation by MSM Country
More informationHEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden)
HEV Update Blood Components Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden) Outline ECDC activities started in 2015 to understand the epidemiology and burden of HEV infection
More informationFailure of Routine HIV-1 Tests in a Case Involving Transmission With Preseroconversion Blood Components During the Infectious Window Period
CLINICAL INVESTIGATION Failure of Routine HIV-1 Tests in a Case Involving Transmission With Preseroconversion Blood Components During the Infectious Window Period Ai Ee Ling, MD Kenneth E. Robbins, BS
More informationThe Food and Drug Administration (FDA) has
NAT Comparative analysis of triplex nucleic acid test assays in United States blood donors Susan L. Stramer, David E. Krysztof, Jaye P. Brodsky, Tracy A. Fickett, Benjamin Reynolds, Roger Y. Dodd, and
More informationKhalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationHIV-1 Seroconversion Panel
A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The Seroconversion is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers
More informationP0141 HBV 1000 copies/ml genotype reference panel
P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents
More informationRoutine NAT-screening for West Nile Virus Infections in Germany: Being prepared
Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared R. Thermann, W. K. Roth IPFA / PEI 18 th international workshop on Surveillance and screening of blood borne pathogens Budapest,
More informationGuidance for Industry
Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately
More informationExpression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed
Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single
More informationConfirmatory Testing Algorithm. Routine Donor Testing Algorithm
Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution
More informationSituation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011
Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients
More informationHIV-RNA reference panels
The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HIV-RNA panels for sensitivity analysis...
More informationDetection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing
The new england journal of medicine original article Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing Susan L. Stramer, Ph.D., Simone A.
More information2014/LSIF/PD/030 Risk Assessment and Cost-Effectiveness of Blood Safety Interventions for HIV, HCV, and HBV Development of a Web-Based Application
2014/LSIF/PD/030 Risk Assessment and Cost-Effectiveness of Blood Safety Interventions for HIV, HCV, and HBV Development of a Web-Based Application Submitted by: Blood Systems Research Institute (BSRI)
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationDENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo
DENGUE AND BLOOD SAFETY Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo Dengue virus Arbovirus (arthropod-borne virus) virus transmitted by mosquitoes:
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationSupplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
More informationExternal Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience
External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di
More informationAccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
More informationRole and missions of a National Reference center for blood borne agents: the French example
Role and missions of a National Reference center for blood borne agents: the French example Virginie Sauvage, PhD Département des Agents Transmissibles par le Sang, Centre National de Référence pour les
More informationP0069 ViraQ HBV Trend 25 P0069
P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationP0154 ViraQ HBV Trend 50 P0154
P0154 ViraQ HBV Trend 50 P0154 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3
More informationHIV-1 Seroconversion Panel
OVERVIEW This Data Sheet contains test results specific for HIV-1. s are undiluted aliquots from plasma units collected from a single donor. No preservatives were added. CAUTION: Potentially infectious
More informationHepa%%s E Virus Is it a Concern?
IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido
More informationHIV-1 Seroconversion Panel PRB964
A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers and clinical
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationExperience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control
Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the
More informationDengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO
Dengue Virus Member of the genus Flavivirus Transmitted by the Aedes mosquito; mosquito => human cycle 4 serotypes: DENV1, 2, 3, and 4 Homotypic immunity is long lasting Heterotypic immunity is short lived
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationHepatitis E virus genotype 3 : what we know so far
Hepatitis E virus genotype 3 : what we know so far May 20 th, 2015 Hans L. Zaaijer MD PhD Sanquin - Blood-borne Infections & Academic Medical Centre - Clinical Virology Amsterdam NL HEV gt 3: the issues
More informationWPTTID / Virology subgroup Activities
WPTTID / Virology subgroup 2010 2011 Activities Progress on previously launched collaborative Projects International Survey on NAT Testing of Blood Donations: Expanding Implementation and Yield from 1999
More information2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
More informationKeeping blood transfusions safe:
ISP-WIV Seminar Diagnosis and surveillance of infectious diseases May 18 th, 2017 Keeping blood transfusions safe: the challenge of emerging infectious diseases Presented by Roland HÜBNER Superior Health
More informationISBT TTI WP HBV safety subgroup. Review and update
ISBT TTI WP HBV safety subgroup Review and update Distribution of dominant HBV genotypes countries & centres participating in HBV studies A2/A1 0.1-0.5 A2 D 0.1-8 B/C F 1-5 E 12-25 5-12 A1 4-8 A2/C HBV
More informationAccuSet Anti-HIV-1 Mixed Titer Performance Panel
signal to cut-off (s/co) DATA SHEET OVERVIEW PRB205(M3) is a modified 16-member panel originating from Anti- HIV-1 Mixed Titer PRB205(M2). Panel members 3, 5, 6, 17, 21, 22, 23, 24, and 25 from the original
More informationHepatitis E and the English blood supply
Hepatitis E and the English blood supply Mhairi Webster Microbiology Senior Scientist National Transfusion Microbiology Reference Laboratory With thanks to Dr Alan Kitchen Hepatitis E virus Small, non-enveloped
More informationImmunohematology. IH-QC Modular System. Select. Combine. Control.
Immunohematology IH-QC Modular System Select. Combine. Control. IH-QC Modular System Select. Combine. Control. Transfusion guidelines recommend regular checking of test materials, test methods, local working
More informationCHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
More informationGuidance for Industry
Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757
More informationGuidance for Industry
Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test
More informationDISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS
DISCOVERY OF FALSE HIV ELITE CONTROLLERS AMONG SOUTH AFRICAN BLOOD DONORS ISBT TTID WP 17 June 2017 Marion Vermeulen, Karin van den Berg, Genevieve Jacobs, Brian Custer, Ronel Swanevelder, Ute Jentsch,
More informationDaniel P. Kolk,* Janel Dockter, Jeff Linnen, Marcy Ho-Sing-Loy, Kristin Gillotte-Taylor, Sherrol H. McDonough, Larry Mimms, and Cristina Giachetti
JOURNAL OF CLINICAL MICROBIOLOGY, May 2002, p. 1761 1766 Vol. 40, No. 5 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.5.1761 1766.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAccuSet Anti-HIV-1 Mixed Titer Performance Panel
PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test
More informationPlasma for fractionation: South African Plasma Requirements
Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal
More informationHIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings
HIV Testing and Systems for Managing HIV Implementation in Resource Limited Settings Elizabeth M. Dax with the staff of the National Serology Reference Laboratory, Australia My Background Worked in HIV
More informationOriginal article J Bas Res Med Sci 2017; 4(2):4-8.
Prevalence of HIV, hepatitis B and C infections among volunteer blood donors at the blood transfusion center of Ilam city, Iran Hasan Boustani 1, Enayat Anvari 2, Sedighe Saiadi Sartang 2, Mehdi Omidi
More informationThe testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 1995, by the Massachusetts Medical Society Volume 333 DECEMBER 28, 1995 Number 26 ESTIMATED RISK OF TRANSMISSION OF THE HUMAN IMMUNODEFICIENCY VIRUS BY SCREENED BLOOD IN THE UNITED STATES EVE
More informationMethodologic issues relating to the use of STARHS to determine HIV incidence: The Ontario experience
Methodologic issues relating to the use of STARHS to determine HIV incidence: The Ontario experience Robert S. Remis MD, MPH Department of Public Health Sciences, University of Toronto National HIV Prevention
More informationHepatitis B viral safety of blood donations: new gaps identified
Editorial Page 1 of 5 Hepatitis B viral safety of blood donations: new gaps identified Wolfram H. Gerlich, Dieter Glebe, Christian G. Schüttler Institute of Medical Virology, National Reference Centre
More information